The updated guidelines broaden the high-risk criteria for children aged 8 to 19 months entering their second RSV season.

Following Fast Track designation, a phase 2a trial will evaluate inhaled treprostinil (Yutrepia) as a potential first-in-class therapy for Raynaud phenomenon in systemic sclerosis.

Blood-based test identifies presence of amyloid plaques in symptomatic adults and is intended to be used in conjunction with a clinical assessment ...